<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33050663</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1420-3049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>20</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecules (Basel, Switzerland)</Title>
          <ISOAbbreviation>Molecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Drug-Eluting Stents and Balloons-Materials, Structure Designs, and Coating Techniques: A Review.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">4624</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules25204624</ELocationID>
        <Abstract>
          <AbstractText>Controlled drug delivery is a matter of interest to numerous scientists from various domains, as well as an essential issue for society as a whole. In the treatment of many diseases, it is crucial to control the dosing of a drug for a long time and thus maintain its optimal concentration in the tissue. Heart diseases are particularly important in this aspect. One such disease is an obstructive arterial disease affecting millions of people around the world. In recent years, stents and balloon catheters have reached a significant position in the treatment of this condition. Balloon catheters are also successfully used to manage tear ducts, paranasal sinuses, or salivary glands disorders. Modern technology is continually striving to improve the results of previous generations of stents and balloon catheters by refining their design, structure, and constituent materials. These advances result in the development of both successive models of drug-eluting stents (DES) and drug-eluting balloons (DEB). This paper presents milestones in the development of DES and DEB, which are a significant option in the treatment of coronary artery diseases. This report reviews the works related to achievements in construction designs and materials, as well as preparation technologies, of DES and DEB. Special attention was paid to the polymeric biodegradable materials used in the production of the above-mentioned devices. Information was also collected on the various methods of producing drug release coatings and their effectiveness in releasing the active substance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rykowska</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-8370-3734</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nowak</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-2426-6722</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nowak</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Eye Department, J. Strus City Hospital, Szwajcarska 3, 61-285 Poznań, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Molecules</MedlineTA>
        <NlmUniqueID>100964009</NlmUniqueID>
        <ISSNLinking>1420-3049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054855" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">controlled drug delivery</Keyword>
        <Keyword MajorTopicYN="N">drug-eluting balloons</Keyword>
        <Keyword MajorTopicYN="N">drug-eluting stents</Keyword>
        <Keyword MajorTopicYN="N">polymers</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33050663</ArticleId>
        <ArticleId IdType="pmc">PMC7594099</ArticleId>
        <ArticleId IdType="doi">10.3390/molecules25204624</ArticleId>
        <ArticleId IdType="pii">molecules25204624</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen D., Jepson N. Coronary stent technology: A narrative review. Med. J. Aust. 2016;205:277–281. doi: 10.5694/mja16.00444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5694/mja16.00444</ArticleId>
            <ArticleId IdType="pubmed">27627940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borhani S., Hassanajili S., Tafti S.H.A., Rabbani S. Cardiovascular stents: Overview, evolution, and next generation. Prog. Biomater. 2018;7:175–205. doi: 10.1007/s40204-018-0097-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40204-018-0097-y</ArticleId>
            <ArticleId IdType="pmc">PMC6173682</ArticleId>
            <ArticleId IdType="pubmed">30203125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Driver M.  Coatings for Biomedical Applications. Woodhead Publishing; Sawston, UK: 2012. Coatings for cardiovascular devices: Coronary stents; pp. 223–250.</Citation>
        </Reference>
        <Reference>
          <Citation>Guildford A., Santin M., Phillips G.  Cardiovascular stents A2-Gourlay, terence. In: Black R.A., editor. Biomaterials and Devices for the Circulatory System. Volume 7. Woodhead Publishing; Sawston, UK: 2010. pp. 173–216.</Citation>
        </Reference>
        <Reference>
          <Citation>Grüntzig A.  Percutaneous Vascular Recanalization. Springer; Berlin/Heidelberg, Germany: 1978. Transluminal dilatation of coronary artery stenosis experimental report; pp. 57–65.</Citation>
        </Reference>
        <Reference>
          <Citation>Sigwart U., Urban P., Golf S., Kaufmann U., Imbert C., Fischer A., Kappenberger L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78:1121–1127. doi: 10.1161/01.CIR.78.5.1121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.78.5.1121</ArticleId>
            <ArticleId IdType="pubmed">3180371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmaz J.C., Kopp D.T., Hayashi H., Schatz R.A., Hunter G., Tio F.O., Garcia O., Alvarado R., Rees C., Thomas S.C. Normal and stenotic renal arteries: Experimental balloon-expandable intraluminal stenting. Radiology. 1987;164:705–708. doi: 10.1148/radiology.164.3.2956628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiology.164.3.2956628</ArticleId>
            <ArticleId IdType="pubmed">2956628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabow N., Martin D.P., Schmitz K.P., Sternberg K. Absorbable polymer stent technologies for vascular regeneration. J. Chem. Technol. Biotechnol. 2009;85:744–751. doi: 10.1002/jctb.2282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jctb.2282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buccheri D., Piraino D., Giuseppe Andolina G., Cortese B. Understanding and managing in-stent restenosis: A review of clinical data, from pathogenesis to treatment. J. Thorac. Dis. 2016;8:E1150–E1162. doi: 10.21037/jtd.2016.10.93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2016.10.93</ArticleId>
            <ArticleId IdType="pmc">PMC5107494</ArticleId>
            <ArticleId IdType="pubmed">27867580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohn J., Zeltinger J. Degradable, drug-eluting stents: A new frontier for the treatment of coronary artery disease. Expert Rev. Med. Devices. 2005;2:667–671. doi: 10.1586/17434440.2.6.667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/17434440.2.6.667</ArticleId>
            <ArticleId IdType="pubmed">16293093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu T., Yang J., Cui K., Rao O., Yin T., Tan L., Zhang Y., Li Z., Wang G. Controlled slow-release drug-eluting stents for the prevention of coronary restenosis: Recent progress and future prospects. ACS Appl. Mater. Interfaces. 2015;7:11695–11712. doi: 10.1021/acsami.5b01993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.5b01993</ArticleId>
            <ArticleId IdType="pubmed">26011753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferns G.A., Avades T.Y. The mechanisms of coronary restenosis: Insights from experimental models. Int. J. Exp. Pathol. 2000;81:63–88. doi: 10.1046/j.1365-2613.2000.00143.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2613.2000.00143.x</ArticleId>
            <ArticleId IdType="pmc">PMC2517722</ArticleId>
            <ArticleId IdType="pubmed">10762439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saleh Y.E., Gepreel M.A., Allam N.K. Functional nanoarchitectures for enhanced drug eluting stents. Sci. Rep. 2017;7:40291. doi: 10.1038/srep40291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep40291</ArticleId>
            <ArticleId IdType="pmc">PMC5227685</ArticleId>
            <ArticleId IdType="pubmed">28079127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bukka M., Rednam P.J., Sinha M. Drug-eluting balloon: Design, technology and clinical aspects. Biomed. Mater. 2018;13:032001. doi: 10.1088/1748-605X/aaa0aa.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1088/1748-605X/aaa0aa</ArticleId>
            <ArticleId IdType="pubmed">29227279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farah S. Protective layer development for enhancing stability and drug-delivery capabilities of des surface-crystallized coatings. ACS Appl. Mater. Interfaces. 2018;10:9010–9022. doi: 10.1021/acsami.7b18733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.7b18733</ArticleId>
            <ArticleId IdType="pubmed">29436817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy Y., Tal N., Tzemach G., Weinberger J., Domb A.J., Mandler D. Drug-eluting stent with improved durability and controllability properties, obtained via electrocoated adhesive promotion layer. J. Biomed. Mater. Res. Part B. 2009;91:819–830. doi: 10.1002/jbm.b.31461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbm.b.31461</ArticleId>
            <ArticleId IdType="pubmed">19582851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori H., Otsuka F., Gupta A., Jinnouchi H., Torii S., Harari E., Virmani R. Revisiting the role of durable polymers in cardiovascular devices. Expert Rev. Cardiovasc. Ther. 2017;15:835–846. doi: 10.1080/14779072.2017.1386098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14779072.2017.1386098</ArticleId>
            <ArticleId IdType="pubmed">28990450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prendergast P., Lally C., Daly S., Reid A., Lee T., Quinn D., Dolan F. Analysis of 18 in cardiovascular stents: A constitutive equation for vascular tissue and finite-element modelling. J. Biomech. Eng. 2003;125:692–699. doi: 10.1115/1.1613674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1115/1.1613674</ArticleId>
            <ArticleId IdType="pubmed">14618928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander G.C., Hwang P.T., Chen J., Kim J., Brott B.C., Yoon Y.S., Jun H.W. Nanomatrix coated stent enhances endothelialization but reduces platelet, smooth muscle cell, and monocyte adhesion under physiologic conditions. ACS Biomater. Sci. Eng. 2017;4:107–115. doi: 10.1021/acsbiomaterials.7b00676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsbiomaterials.7b00676</ArticleId>
            <ArticleId IdType="pmc">PMC6752702</ArticleId>
            <ArticleId IdType="pubmed">31538110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balakrishnan B., Dooley J.F., Kopia G., Edelman E.R. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J. Control. Release. 2007;123:100–108. doi: 10.1016/j.jconrel.2007.06.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2007.06.025</ArticleId>
            <ArticleId IdType="pmc">PMC2702153</ArticleId>
            <ArticleId IdType="pubmed">17868948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Htay T., Liu M.W. Drug-Eluting Stent: A Review and Update. Vasc. Health Risk Manag. 2005;1:263–276. doi: 10.2147/vhrm.2005.1.4.263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/vhrm.2005.1.4.263</ArticleId>
            <ArticleId IdType="pmc">PMC1993957</ArticleId>
            <ArticleId IdType="pubmed">17315599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burt H.M., Hunter W.L. Drug-eluting stents: A multidisciplinary success story. Adv. Drug Deliv. Rev. 2006;3:350–357. doi: 10.1016/j.addr.2006.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2006.01.014</ArticleId>
            <ArticleId IdType="pubmed">16546288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin D.M., Boyle F.J. Drug-eluting stents for coronary artery disease: A review. Med. Eng. Phys. 2011;33:148–163. doi: 10.1016/j.medengphy.2010.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medengphy.2010.10.009</ArticleId>
            <ArticleId IdType="pubmed">21075668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doostzadeh J., Clark L.N., Bezenek S., Pierson W., Sood P.R., Sudhir K. Recent progress in percutaneous coronary intervention: Evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron. Artery Dis. 2010;21:46–56. doi: 10.1097/MCA.0b013e328333f550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCA.0b013e328333f550</ArticleId>
            <ArticleId IdType="pubmed">19952925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silber S., Herdeg C. Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials. Herz Kardiovask. Erkrank. 2008;33:196–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18568314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Bhindi R., Khachigian L.M. Recent developments in drug-eluting stents. J. Mol. Med. 2011;89:545–553. doi: 10.1007/s00109-011-0729-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-011-0729-3</ArticleId>
            <ArticleId IdType="pubmed">21279500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchanan K., Steinvil A., Waksman R. Does the new generation of drug-eluting stents render bare metal stents obsolete? Cardiovasc. Revascularization Med. 2017;18:456–461. doi: 10.1016/j.carrev.2017.03.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.carrev.2017.03.027</ArticleId>
            <ArticleId IdType="pubmed">28941481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fusaro M., Cassese S., Ndrepepa G., Tepe G., King L., Ott I., Nerad M., Schunkert H., Kastrati A. Drug-eluting stents for revascularization of infrapopliteal arteries: Updated meta-analysis of randomized trials. JACC Cardiovasc. Interv. 2013;6:1284–1293. doi: 10.1016/j.jcin.2013.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2013.08.007</ArticleId>
            <ArticleId IdType="pubmed">24355118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shlofmitz E., Iantorno M., Waksman R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review. Circ. Cardiovasc. Interv. 2019;12:e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.118.007023</ArticleId>
            <ArticleId IdType="pubmed">31345066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiesinger C.G., Lee J., Herrera-Caceres J.O. Future developments in ureteral stents. Curr. Opin. Urol. 2019;29:124–128. doi: 10.1097/MOU.0000000000000577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOU.0000000000000577</ArticleId>
            <ArticleId IdType="pubmed">30531433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lukman S.K., Al-Ashwal R.H., Khudzari A.Z.M., Saidin S. Emerging of cardiovascular metal stent: A review on drug-eluting stent towards the utilisation of herbal coating. Malays. J. Fundam. Appl. Sci. 2019;15:225–231. doi: 10.11113/mjfas.v15n2.1115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.11113/mjfas.v15n2.1115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J.J., Way J.A.H., Kritharides L., Brieger D. Polymer-free versus durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. Ann. Med. Surg. 2019;38:13–21. doi: 10.1016/j.amsu.2018.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amsu.2018.12.003</ArticleId>
            <ArticleId IdType="pmc">PMC6302254</ArticleId>
            <ArticleId IdType="pubmed">30581571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kommineni N., Saka R., Khan W., Domb A. Non-polymer drug-eluting coronary stents. Drug Deliv. Transl. Res. 2018;8:903–917. doi: 10.1007/s13346-017-0414-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13346-017-0414-3</ArticleId>
            <ArticleId IdType="pubmed">28799125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livingston M., Tan A. Coating Techniques and Release Kinetics of Drug-Eluting Stents. Med. Devices. 2019;10 doi: 10.1115/1.4031718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1115/1.4031718</ArticleId>
            <ArticleId IdType="pmc">PMC6542673</ArticleId>
            <ArticleId IdType="pubmed">31156736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tousoulis D., Oikonomou E., Economou E.K., Crea F., Kaski J.C. Inflammatory cytokines in atherosclerosis: Current therapeutic approaches. Eur. Heart J. 2016;37:1723–1732. doi: 10.1093/eurheartj/ehv759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehv759</ArticleId>
            <ArticleId IdType="pubmed">26843277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simard T., Hibbert B., Ramirez F.D., Froeschl M., Chen Y.X., O’Brien E.R. The evolution of coronary stents: A brief review. Can. J. Cardiol. 2014;30:35–45. doi: 10.1016/j.cjca.2013.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cjca.2013.09.012</ArticleId>
            <ArticleId IdType="pubmed">24286961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W., Habraken T.C., Hennink W.E., Kok R.J. Polymer-free drug-eluting stents: An overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjug. Chem. 2015;26:1277–1288. doi: 10.1021/acs.bioconjchem.5b00192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.bioconjchem.5b00192</ArticleId>
            <ArticleId IdType="pubmed">26041505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tugtekin S.M., Kappert U., Jung F., Park J.W., Knaut M. Do drugeluting stents influence the spectrum of coronary artery bypass surgery? Herz. 2004;29:201–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15057442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy Y., Mandler D., Weinberger J., Domb A.J. Evaluation of drug-eluting stents’ coating durability-clinical and regulatory implications. J. Biomed. Mater. Res. Part B. 2009;91:441–451. doi: 10.1002/jbm.b.31420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbm.b.31420</ArticleId>
            <ArticleId IdType="pubmed">19489011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker T., Dave V., Falotico R. Polymers for drug eluting stents. Curr. Pharm. Des. 2010;16:3978–3988. doi: 10.2174/138161210794454897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161210794454897</ArticleId>
            <ArticleId IdType="pubmed">21208188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naseem R., Zhao L., Liu Y., Silberschmidt V.V. Experimental and computational studies of poly-l-lactic acid for cardiovascular applications: Recent progress. Mech. Adv. Mater. Modern Process. 2017;3:13–21. doi: 10.1186/s40759-017-0028-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40759-017-0028-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celermajer D.S. Endothelial dysfunction: Does it matter? Is it reversible? J. Am. Coll. Cardiol. 1997;30:325–333. doi: 10.1016/S0735-1097(97)00189-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-1097(97)00189-7</ArticleId>
            <ArticleId IdType="pubmed">9247501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberhauser J.P., Hossainy S., Rapoza R.J. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009;5:F15–F22. doi: 10.4244/EIJV5IFA3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4244/EIJV5IFA3</ArticleId>
            <ArticleId IdType="pubmed">22100671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wayangankar S.A., Ellis S.G. Bioresorbable stents: Is this where we are headed? Prog. Cardiovasc. Dis. 2015;58:342–355. doi: 10.1016/j.pcad.2015.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pcad.2015.08.011</ArticleId>
            <ArticleId IdType="pubmed">26319497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiebe J., Nef H.M., Hamm C.W. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J. Am. Coll. Cardiol. 2014;64:2541–2551. doi: 10.1016/j.jacc.2014.09.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2014.09.041</ArticleId>
            <ArticleId IdType="pubmed">25500240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariano E., Sangiorgi G.M., Fioranelli M.  Imaging Coronary Arteries. Springer; New York, NY, USA: 2013. Coronary stents; pp. 101–113.</Citation>
        </Reference>
        <Reference>
          <Citation>Bourantas C.V., Onuma Y., Farooq V., Zhang Y., Serruys H.M., Garcia-Garcia P.W. Bioresorbable scaffolds: Current knowledge, potentialities and limitations experienced during their first clinical applications. Int. J. Cardiol. 2013;167:11–21. doi: 10.1016/j.ijcard.2012.05.093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2012.05.093</ArticleId>
            <ArticleId IdType="pubmed">22748288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kereiakes D.J., Onuma Y., Serruys P.W., Stone G.W. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;134:168–182. doi: 10.1161/CIRCULATIONAHA.116.021539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.021539</ArticleId>
            <ArticleId IdType="pubmed">27400899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onuma Y., Serruys P.W. Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779–797. doi: 10.1161/CIRCULATIONAHA.110.971606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.971606</ArticleId>
            <ArticleId IdType="pubmed">21343594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharkawi T., Cornhill F., Lafont A., Sabaria P., Vert M. Intravascular bioresorbable polymeric stents: A potential alternative to current drug eluting metal stents. J. Pharm. Sci. 2007;96:2829–2837. doi: 10.1002/jps.20957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.20957</ArticleId>
            <ArticleId IdType="pubmed">17979210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergström J.S., Hayman D. An overview of mechanical properties and material modeling of polylactide (PLA) for medical applications. Ann. Biomed. Eng. 2016;44:330–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26369638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizas K.D., Mehilli J. Stent Polymers Do They Make a Difference? Circ. Cardiovasc. Interv. 2016;9:e002943. doi: 10.1161/CIRCINTERVENTIONS.115.002943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.115.002943</ArticleId>
            <ArticleId IdType="pubmed">27193905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart S.A., Domínguez-Robles J., Donnelly R.F., Larrañeta E. Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. Polymers. 2018;10:1379.  doi: 10.3390/polym10121379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/polym10121379</ArticleId>
            <ArticleId IdType="pmc">PMC6401754</ArticleId>
            <ArticleId IdType="pubmed">30961303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strohbach A., Busch R. Polymers for Cardiovascular Stent Coatings. Review. Int. J. Polym. Sci. 2015 doi: 10.1155/2015/782653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/782653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph J., Patel R.M., Wenham A., Smith J.R. Biomedical applications of polyurethane materials and coatings. Trans. Inst. Met. Finish. 2018;96:121–129. doi: 10.1080/00202967.2018.1450209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00202967.2018.1450209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Englert C., Brendel J.C., Majdanski T.C., Yildirim T., Schubert S., Gottschaldt M., Windhab N., Schubert U.S. Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications. Prog. Polym. Sci. 2018;87:107–164. doi: 10.1016/j.progpolymsci.2018.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.progpolymsci.2018.07.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao T., Wang J., Zeng Y., Liu G., Chen X. Polysaccharide-based controlledrelease systems for therapeutics delivery and tissue engineering: Frombench to bedside. Adv. Sci. 2018;5:1700513. doi: 10.1002/advs.201700513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/advs.201700513</ArticleId>
            <ArticleId IdType="pmc">PMC5908359</ArticleId>
            <ArticleId IdType="pubmed">29721408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nair L.S., Laurencin C.T. Biodegradable polymers as biomaterials. Prog. Polym. Sci. 2007;32:762–798. doi: 10.1016/j.progpolymsci.2007.05.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.progpolymsci.2007.05.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shavi G.V., Averineni R.K., Bhat M., Udupa N., Upadhya P.N. Poly(-hydroxy acid)based polymers: A review on material and degradation aspects. Polym. Degrad. Stab. 2017;144:520–535.</Citation>
        </Reference>
        <Reference>
          <Citation>Grayson A.C.R., Voskerician G., Lynn A., Anderson J.M., Cima M.J., Langer R. Differential degradationrates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J. Biomater. Sci. Polym. Ed. 2004;15:1281–1304. doi: 10.1163/1568562041959991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1163/1568562041959991</ArticleId>
            <ArticleId IdType="pubmed">15559850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulery B.D., Nair L.S., Laurencin C.T. Biomedical applications of biodegradable polymers. J. Polym. Sci. Part B Polym. Phys. 2011;49:832–864. doi: 10.1002/polb.22259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/polb.22259</ArticleId>
            <ArticleId IdType="pmc">PMC3136871</ArticleId>
            <ArticleId IdType="pubmed">21769165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Middleton J.C., Tipton A.J. Synthetic biodegradable polymers as orthopedic devices. Biomaterials. 2000;21:2335–2346. doi: 10.1016/S0142-9612(00)00101-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0142-9612(00)00101-0</ArticleId>
            <ArticleId IdType="pubmed">11055281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crimi G., Gritti V., Galiffa V.A., Scotti V., Leonardi S., Ferrario M., Ferlini M., De Ferrari G.M., Visconti L.O., Klersy C. Drugeluting stents are superior to bare metal stents to reduce clinical outcomeand stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis. J. Interven. Cardiol. 2018;31:319–329. doi: 10.1111/joic.12473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joic.12473</ArticleId>
            <ArticleId IdType="pubmed">29285790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmerini T., Biondi-Zoccai G., Della Riva D., Mariani A., Genereux P., Branzi A., Stone G.W. Stent thrombosis with drug-eluting stents: Is the paradigm shifting? J. Coll. Cardiol. 2013;62:1915–1921. doi: 10.1016/j.jacc.2013.08.725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2013.08.725</ArticleId>
            <ArticleId IdType="pubmed">24036025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin-Quee S.L., Hsu S.H., Nguyen-Ehrenreich K.L., Tai J.T., Abraham G.M., Pacetti S.D., Chan Y.F., Nakazawa G., Kolodgie F.D., Virmani R., et al.  Endothelial cell recovery, acute thrombogenicity, and monocyteadhesion and activation on fluorinated copolymer and phosphorylcholinepolymer stent coatings. Biomaterials. 2010;31:648–657. doi: 10.1016/j.biomaterials.2009.09.079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2009.09.079</ArticleId>
            <ArticleId IdType="pubmed">19822362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y., Ng H.C.A., Ng X.W., Subbu V. Drug-eluting biostable and erodiblestents. J. Control. Release. 2014;193:188–201. doi: 10.1016/j.jconrel.2014.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2014.05.011</ArticleId>
            <ArticleId IdType="pubmed">24845127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iqbal J.J., Gunn P.W. Serruys, Coronary stents: Historical development, currentstatus and future directions. Br. Med. Bull. 2013;106:193–211. doi: 10.1093/bmb/ldt009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bmb/ldt009</ArticleId>
            <ArticleId IdType="pubmed">23532779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tada T., Byrne R.A., Cassese S., King L., Schulz S., Mehilli J., Schömig A., Kastrati A. Comparativeefficacy of 2 zotarolimus-eluting stent generations: Resolute versus endeavor stents in patients with coronary artery disease. Am. Heart J. 2013;165:80–86. doi: 10.1016/j.ahj.2012.10.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ahj.2012.10.019</ArticleId>
            <ArticleId IdType="pubmed">23237137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gogas B.D., McDaniel M., Samady H., King S.B.I. Novel drug-eluting stents forcoronary revascularization. Trends Cardiovasc. Med. 2014;24:305–313. doi: 10.1016/j.tcm.2014.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcm.2014.07.004</ArticleId>
            <ArticleId IdType="pubmed">25240980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sammel A.M., Chen D., Jepson N. New generation coronary stenttechnology—Is the future biodegradable? Heart Lung. Circ. 2013;22:495–506. doi: 10.1016/j.hlc.2013.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.hlc.2013.02.008</ArticleId>
            <ArticleId IdType="pubmed">23548335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bundhun P.K., Pursun M., Huang F. Biodegradable polymer drug-eluting stentsversus first-generation durable polymer drug-eluting stents: A systematicreview and meta-analysis of 12 randomized controlled trials. Medicine. 2017;96:e8878. doi: 10.1097/MD.0000000000008878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000008878</ArticleId>
            <ArticleId IdType="pmc">PMC5709010</ArticleId>
            <ArticleId IdType="pubmed">29382011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogic J., Mc Cormick L.M., Francis R., Nerlekar N., Jaworski C., West N.E.J., Brown A.J. Novel bioabsorbable polymer and polymer-free metallic drug-elutingstents. Int. J. Cardiol. 2018;71:435–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29338896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefanini G.G., Kalesan B., Serruys P.W., Heg D., Buszman P., Linke A., Ischinger T., Klauss V., Eberli F., Wijns W., et al.  Long-term clinical outcomes of biodegradable polymer biolimus-elutingstents versus durable polymer sirolimus-eluting stents in patients withcoronary artery disease (LEADERS): 4-year follow-up of a randomisednon-inferiority trial. Lancet. 2011;378:1940–1948. doi: 10.1016/S0140-6736(11)61672-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(11)61672-3</ArticleId>
            <ArticleId IdType="pubmed">22075451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Upendra K., Sanjeev B. Advantages of novel BioMimeTM sirolimus elutingcoronary stent system. Mov. Towards Biomimicry. Minerva Cardioangiol. 2012;60:23–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22322571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemos P.A., Bienert I. The supralimus®sirolimus-eluting stent. Exp. Rev. Med. Devices. 2013;10:295–300. doi: 10.1586/erd.12.91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erd.12.91</ArticleId>
            <ArticleId IdType="pubmed">23597097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kereiakes D.J., Meredith I.T., Windecker S., Jobe R.L., Mehta S.R., Sarembock I.J., Feldman R.L., Stein B., Dubois C., Grady T., et al.  Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: The EVOLVE II randomized trial. Circ. Cardiovasc. Interv. 2015;8:e002372. doi: 10.1161/CIRCINTERVENTIONS.114.002372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.114.002372</ArticleId>
            <ArticleId IdType="pubmed">25855680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen L.O., Thayssen P., Maeng M., Ravkilde J., Hansen H.S., Jensen S.E., Krusell L.R., Raungaard B., Junker A., Terkelsen C.J., et al.  Randomized comparison of a sirolimus-eluting orsiro stent with abiolimus-eluting nobori stent in patients treated with percutaneouscoronary intervention: Rationale and study design of the scandinavianorganization for randomized trials with clinical outcome VII trial. Am. Heart J. 2015;170:210–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26299216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner E., Megan E., Atigh M., Christians U., Saul J.M., Yazdani S.K. In vitro and in vivo Assessment of Keratose as a Novel Excipient of Paclitaxel Coated Balloons. Front Pharmacol. 2018;9:808–813. doi: 10.3389/fphar.2018.00808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.00808</ArticleId>
            <ArticleId IdType="pmc">PMC6078047</ArticleId>
            <ArticleId IdType="pubmed">30104972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21:2475–2490. doi: 10.1016/S0142-9612(00)00115-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0142-9612(00)00115-0</ArticleId>
            <ArticleId IdType="pubmed">11055295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles-based drug delivery systems. Coll. Surf. B Biointerfaces. 2010;75:1–18. doi: 10.1016/j.colsurfb.2009.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2009.09.001</ArticleId>
            <ArticleId IdType="pubmed">19782542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997;28:5–24. doi: 10.1016/S0169-409X(97)00048-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0169-409X(97)00048-3</ArticleId>
            <ArticleId IdType="pubmed">10837562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makadia H.K., Siegel S.J. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377–1397. doi: 10.3390/polym3031377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/polym3031377</ArticleId>
            <ArticleId IdType="pmc">PMC3347861</ArticleId>
            <ArticleId IdType="pubmed">22577513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farah S., Anderson D.G., Langer R. Physical and mechanical properties of PLA, and their functions in widespread applications-A comprehensive review. Adv. Drug Deliv. Rev. 2016;107:367–392. doi: 10.1016/j.addr.2016.06.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2016.06.012</ArticleId>
            <ArticleId IdType="pubmed">27356150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukherjee T., Kao N. PLA Based Biopolymer Reinforced with Natural Fibre: A Review. J. Polym. Environ. 2011;19:714–725. doi: 10.1007/s10924-011-0320-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10924-011-0320-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Silva D., Kaduri M., Poley M., Adir O., Krinsky N., Shainsky-Roitman J., Schroeder A. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems. Chem. Eng. J. 2018;340:9–14. doi: 10.1016/j.cej.2018.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cej.2018.01.010</ArticleId>
            <ArticleId IdType="pmc">PMC6682490</ArticleId>
            <ArticleId IdType="pubmed">31384170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao L., Wang B., Yang G., Gauthier M.  Biomedical Science. Engineering and Technology InTech; London, UK: 2012. Poly(Lactic Acid)-Based Biomaterials: Synthesis, Modification and Applications.</Citation>
        </Reference>
        <Reference>
          <Citation>Avérous L., Pollet E.  Environmental Silicate Nano-Biocomposites. In: Avérous L., Pollet E., editors. Green Energy and Technology. Springer; London, UK: 2012. </Citation>
        </Reference>
        <Reference>
          <Citation>Bao L., Dorgan J.R., Knauss D., Hait S., Oliveira N.S., Maruccho I.M. Gas permeation properties of poly(lactic acid) revisited. J. Membr. Sci. 2006;285:166–172. doi: 10.1016/j.memsci.2006.08.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.memsci.2006.08.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieira A.C., Vieira J.C., Ferra J.M., Magalhăes F.D., Guedes R., Marques A.T. Mechanical study of PLA–PCL fibers during in vitro degradation. J. Mech. Behav. Biomed. Mater. 2011;4:451–460. doi: 10.1016/j.jmbbm.2010.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmbbm.2010.12.006</ArticleId>
            <ArticleId IdType="pubmed">21316633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurus P.B., Kaeding C.C. Bioabsorbable implant material review. Oper. Tech. Sports Med. 2004;12:158–160. doi: 10.1053/j.otsm.2004.07.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.otsm.2004.07.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xinteng Z., Weisan P., Ruhua Z., Feng Z. Preparation and evaluation of poly (D, L-lactic acid) (PLA) or D,L-lactide/glycolide copolymer (PLGA) microspheres with estradiol. Pharmazie. 2002;57:695–697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12426951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamshidian M., Tehrany E.A., Imran M., Jacquot M., Desobry S. Poly-Lactic Acid: Production, Applications, Nanocomposites, and Release Studies. Compr. Rev. Food Sci. Food Saf. 2010;9:552–571. doi: 10.1111/j.1541-4337.2010.00126.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1541-4337.2010.00126.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukushima K., Hirata M., Kimura Y. Synthesis and Characterization of Stereoblock Poly(lactic acid)s with Nonequivalent D/L Sequence Ratios. Macromolecules. 2007;40:3049–3055. doi: 10.1021/ma070156k.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ma070156k</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooney D.J., Baldwin D.F., Suh N.P., Vacanti J.P., Langer R. Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials. 1996;17:1417–1422. doi: 10.1016/0142-9612(96)87284-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0142-9612(96)87284-X</ArticleId>
            <ArticleId IdType="pubmed">8830969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grizzi I., Garreau H., Li S., Vert M. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials. 1995;16:305–311. doi: 10.1016/0142-9612(95)93258-F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0142-9612(95)93258-F</ArticleId>
            <ArticleId IdType="pubmed">7772670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt C.G., Gratzl M.M., Kimmel G.L., Surles J., Schindler A. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. Biomaterials. 1981;2:215–220. doi: 10.1016/0142-9612(81)90060-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0142-9612(81)90060-0</ArticleId>
            <ArticleId IdType="pubmed">7326315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bini R.A., Silva M.F., Varanda L.C., da Silva M.A., Dreiss C.A. Soft nanocomposites of gelatin and poly(3-hydroxybutyrate) nanoparticles for dual drug release. Coll. Surf. B Biointerfaces. 2017;157:191–198. doi: 10.1016/j.colsurfb.2017.05.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2017.05.051</ArticleId>
            <ArticleId IdType="pubmed">28595135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldbart R., Traitel T., Lapidot S.A., Kost J. Enzymatically controlled responsive drug delivery systems. Polym. Adv. Technol. 2002;13:1006–1018. doi: 10.1002/pat.275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pat.275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Athanasiou K., Agrawal C., Barber F., Burkhart S. Orthopaedic applications for PLA-PGA biodegradable polymers. Arthrosc. J. Arthrosc. Relat. Surg. 1998;14:726–737. doi: 10.1016/S0749-8063(98)70099-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0749-8063(98)70099-4</ArticleId>
            <ArticleId IdType="pubmed">9788368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajgor N., Bhaskar V., Patel M. Implantable drug delivery systems: An overview. Syst. Rev. Pharm. 2011;2:91–95. doi: 10.4103/0975-8453.86297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0975-8453.86297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun H., Mei L., Song C., Cui X., Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27:1735–1740. doi: 10.1016/j.biomaterials.2005.09.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2005.09.019</ArticleId>
            <ArticleId IdType="pubmed">16198413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castilla-Cortázar I., Más-Estellés J., Meseguer-Dueñas J.M., Escobar Ivirico J.L., Marí B., Vidaurre A. Hydrolytic and enzymatic degradation of a poly(ε-caprolactone) network. Polym. Degrad. Stab. 2012;97:1241–1248. doi: 10.1016/j.polymdegradstab.2012.05.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.polymdegradstab.2012.05.038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mondal D., Griffith M., Venkatraman S.S. Polycaprolactone-based biomaterials for tissue engineering and drug delivery: Current scenario and challenges. Int. J. Polym. Mater. Polym. Biomater. 2016;65:255–265. doi: 10.1080/00914037.2015.1103241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00914037.2015.1103241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodruff M.A., Hutmacher D.W. The return of a forgotten polymer-Polycaprolactone in the 21st century. Prog. Polym. Sci. 2010;35:1217–1256. doi: 10.1016/j.progpolymsci.2010.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.progpolymsci.2010.04.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenkins M.J., Harrison K.L. The effect of molecular weight on the crystallization kinetics of polycaprolactone. Polym. Adv. Technol. 2006;17:474–478. doi: 10.1002/pat.733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pat.733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escobar Ivirico J.L., Salmerón Sánchez M., Sabater i Serra R., Meseguer Dueñas J.M., Gómez Ribelles J.L., Monleón Pradas M. Structure and Properties of Poly(“-caprolactone) Networks with Modulated Water Uptake. Macromol. Chem. Phys. 2006;207:2195–2205. doi: 10.1002/macp.200600399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/macp.200600399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra R.S., Escobar Ivirico J.L., Meseguer Dueñas J.M. Andrio Balado, A.; Gómez Ribelles, J.L.; Salmerón Sánchez, M. Dielectric relaxation spectrum of poly (Epsilon-caprolactone) networks hydrophilized by copolymerization with 2-hydroxyethyl acrylate. Eur. Phys. J. E. 2007;22:293–302. doi: 10.1140/epje/e2007-00036-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1140/epje/e2007-00036-7</ArticleId>
            <ArticleId IdType="pubmed">17415514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei X.W., Gong C.Y., Gou M.L., Fu S.Z., Guo Q.F., Shi S., Luo F., Guo G., Qiu L.Y., Qian Z.Y. Biodegradable poly(ε-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int. J. Pharm. 2009;381:1–18. doi: 10.1016/j.ijpharm.2009.07.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2009.07.033</ArticleId>
            <ArticleId IdType="pubmed">19664700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhrich K.E., Cannizzaro S.M., Langer R.S., Shakesheff K.M. Polymeric Systems for Controlled Drug Release. Chem. Rev. 1999;99:3181–3198. doi: 10.1021/cr940351u.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cr940351u</ArticleId>
            <ArticleId IdType="pubmed">11749514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doppalapudi S., Jain A., Khan W., Domb A.J. Biodegradable polymers-an overview. Polym. Adv. Technol. 2014;25:427–435. doi: 10.1002/pat.3305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pat.3305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goonoo N., Jeetah R., Bhaw-Luximon A., Jhurry D. Polydioxanone-based biomaterials for tissue engineering and drug/gene delivery applications. Eur. J. Pharm. Biopharm. 2015;97:371–391. doi: 10.1016/j.ejpb.2015.05.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpb.2015.05.024</ArticleId>
            <ArticleId IdType="pubmed">26614558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witte F. Reprint of: The history of biodegradable magnesium implants: A review. Acta Biomater. 2015;23:S28–S40. doi: 10.1016/j.actbio.2015.07.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actbio.2015.07.017</ArticleId>
            <ArticleId IdType="pubmed">26235343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen T.Y., Liew C.G., Liu H. An in vitro mechanism study on the proliferation and pluripotency of human embryonic stems cells in response to magnesium degradation. PLoS ONE. 2013;8:e76547.  doi: 10.1371/journal.pone.0076547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0076547</ArticleId>
            <ArticleId IdType="pmc">PMC3798428</ArticleId>
            <ArticleId IdType="pubmed">24146887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heublein B., Rohde R., Kaese V., Niemeyer M., Hartung W., Haverich A. Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology? Heart. 2003;89:651–656. doi: 10.1136/heart.89.6.651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/heart.89.6.651</ArticleId>
            <ArticleId IdType="pmc">PMC1767674</ArticleId>
            <ArticleId IdType="pubmed">12748224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waksman R., Pakala R., Baffour R., Seabron R., Hellinga D., Tio F.O. Short-term effects of biocorrodible iron stents in porcine coronary arteries. J. Interv. Cardiol. 2008;21:15–20. doi: 10.1111/j.1540-8183.2007.00319.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1540-8183.2007.00319.x</ArticleId>
            <ArticleId IdType="pubmed">18086136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haude M., Erbel R., Erne P., Verheye S., Degen H., Vermeersch P., Weissman N., Prati F., Bruining N., Waksman R., et al.  Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. EuroIntervention. 2016;12:160–166. doi: 10.4244/EIJ-D-15-00371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4244/EIJ-D-15-00371</ArticleId>
            <ArticleId IdType="pubmed">27290675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haude M., Ince H., Abizaid A., Toelg R., Lemos P.A., von Birgelen C., Christiansen E.H., Wijns W., Neumann F.J., Kaiser C., et al.  Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. 2016;387:31–39. doi: 10.1016/S0140-6736(15)00447-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)00447-X</ArticleId>
            <ArticleId IdType="pubmed">26470647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang W., Tian Q., Vuong T., Shashaty M., Gopez C., Sanders T., Liu H. Comparison study on four biodegradable polymer coatings for controlling magnesium degradation and human endothelial cell adhesion and spreading. ACS Biomater. Sci. Eng. 2017;3:936–950. doi: 10.1021/acsbiomaterials.7b00215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsbiomaterials.7b00215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson I., Akari K., Liu H. Nanostructured hydroxyapatite/poly (lactic-co-glycolic acid) composite coating for controlling magnesium degradation in simulated body fluid. Nanotechnology. 2013;24:375103. doi: 10.1088/0957-4484/24/37/375103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1088/0957-4484/24/37/375103</ArticleId>
            <ArticleId IdType="pubmed">23975041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Cao P., Zhang X., Zhang S., He Y. In vitro degradation and cell attachment of a PLGA coated biodegradable Mg–6Zn based alloy. J. Mater. Sci. 2010;45:6038–6045. doi: 10.1007/s10853-010-4688-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10853-010-4688-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J., Wang P., Chu C.C., Xi T. A novel biodegradable and biologically functional arginine-based poly (ester urea urethane) coating for Mg–Zn–Y–Nd alloy: Enhancement in corrosion resistance and biocompatibility. J. Mater. Chem. B. 2017;5:1787–1802. doi: 10.1039/C6TB03147A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C6TB03147A</ArticleId>
            <ArticleId IdType="pubmed">32263920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hornberger H., Virtanen S., Boccaccini A. Biomedical coatings on magnesium alloys—A review. Acta Biomater. 2012;8:2442–2455. doi: 10.1016/j.actbio.2012.04.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actbio.2012.04.012</ArticleId>
            <ArticleId IdType="pubmed">22510401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu P., Fan H., Liu Y., Cao L., Wu X., Xu X. Controllable biodegradability, drug release behavior and hemocompatibility of PTXeluting magnesium stents. Coll. Surf. B. 2011;83:23–28. doi: 10.1016/j.colsurfb.2010.10.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2010.10.038</ArticleId>
            <ArticleId IdType="pubmed">21087842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F.Q., Gu Y.Q., Hua R.X., Ni Z.H., Zhao G.T. In vitro release study of sirolimus from a PDLLA matrix on a bioresorbable drug-eluting stent. J. Drug Deliv. Sci. Technol. 2018;48:88–95. doi: 10.1016/j.jddst.2018.08.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jddst.2018.08.026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarty K., Dalal D.C. An analytical study of drug release kinetics from a degradable polymeric matrix. Int. J. Biomath. 2018;11:1850011. doi: 10.1142/S1793524518500110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1142/S1793524518500110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H.J., Li X.D., Deng W., Wang X.F., Wang S.G., Ge J.B., Toft E. Drug release kinetics from a drug-eluting stent with asymmetrical coat HPLC. Front. Biosci. Landmark. 2017;22:407–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27814621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Wu F., Zhang K., He Z., Zou D., Luo X., Fan Y., Yang P., Zhao A., Huang N. Controlling molecular weight of hyaluronic acid conjugated on amine-rich surface: Toward better multifunctional biomaterials for cardiovascular implants. ACS Appl. Mater. Interfaces. 2017;9:30343–30358. doi: 10.1021/acsami.7b07444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.7b07444</ArticleId>
            <ArticleId IdType="pubmed">28836435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi P., Maitz M.F., Huang N. Surface modification of cardiovascular materials and implants. Surf. Coat. Technol. 2013;233:80–90. doi: 10.1016/j.surfcoat.2013.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surfcoat.2013.02.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo L., Wang G., Li Y., Yin T., Jiang T., Ruan C. Layer-by-layer assembly of chitosan and platelet monoclonal antibody to improve biocompatibility and release character of PLLA coated stent. J. Biomed. Mater. Res. Part A. 2011;97:423–432. doi: 10.1002/jbm.a.33066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbm.a.33066</ArticleId>
            <ArticleId IdType="pubmed">21484986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt H., Menning M. 2000, “Wet Coating Technologies for Glass,” SolGel.com.  [(accessed on 28 September 2020)]; Available online:  http://www.solgel.com/articles/nov00/mennig.htm.</Citation>
        </Reference>
        <Reference>
          <Citation>Ammam M. Electrophoretic Deposition Under Modulated Electric Fields: A Review. RSC Adv. 2012;2:7633–7646. doi: 10.1039/c2ra01342h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c2ra01342h</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leong K., Langer R. Polymeric controlled drug delivery. Adv. Drug Deliv. Rev. 1988;1:199–233. doi: 10.1016/0169-409X(88)90019-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0169-409X(88)90019-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nukala R.K., Boyapally H., Slipper I.J., Mendham A.P., Douroumis D. The Application of Electrostatic Dry Powder Deposition Technology to Coat Drug-Eluting Stents. Pharm. Res. 2010;27:72–81. doi: 10.1007/s11095-009-0008-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-009-0008-y</ArticleId>
            <ArticleId IdType="pubmed">19915963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Wang W., Acharya G., Shim Y.B., Choe E.S., Lee C.H. Advanced Stent Coating for Drug Delivery and In Vivo Biocompatibility. J. Nanopar. Res. 2013;15:1962–1978. doi: 10.1007/s11051-013-1962-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11051-013-1962-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagiwara K., Hasebe T., Hotta A. Effects of Plasma Treatments on the Controlled Drug Release From Poly(Ethylene-co-Vinyl Acetate) Surf. Coat. Technol. 2013;216:318–323. doi: 10.1016/j.surfcoat.2012.11.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surfcoat.2012.11.064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanshan C., Lili T., Yingxue T., Bingchun Z., Ke Y. Study of Drug-Eluting Coating on Metal Coronary Stent, Mater. Sci. Eng. C. 2013;33:1476–1480. doi: 10.1016/j.msec.2012.12.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msec.2012.12.049</ArticleId>
            <ArticleId IdType="pubmed">23827598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín del Valle E.M., Galan M.A., Carbonell R.G. Drug delivery technologies: The way forward in the new decade. Ind. Eng. Chem. Res. 2009;48:2475–2486. doi: 10.1021/ie800886m.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ie800886m</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow A.H., Tong H.H., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007;24:411–437. doi: 10.1007/s11095-006-9174-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-006-9174-3</ArticleId>
            <ArticleId IdType="pubmed">17245651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langer R., Peppas N.A. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 2003;49:2990–3006. doi: 10.1002/aic.690491202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/aic.690491202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam K., Watanabe J., Ishihara K. Modeling of swelling and drug release behavior of spontaneously forming hydrogels composed of phospholipid polymers. Int. J. Pharm. 2004;275:259–269. doi: 10.1016/j.ijpharm.2004.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2004.02.009</ArticleId>
            <ArticleId IdType="pubmed">15081156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis S.S. Drug delivery systems. Interdiscip. Sci. Rev. 2000;25:175–183. doi: 10.1179/030801800679206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/030801800679206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ajili S.H., Ebrahimi N.G., Soleimani M. Polyurethane/polycaprolactane blend with shape memory effect as a proposed material for cardiovascular implants. Acta Biomater. 2009;5:1519–1530. doi: 10.1016/j.actbio.2008.12.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actbio.2008.12.014</ArticleId>
            <ArticleId IdType="pubmed">19249261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navarese E.P., Kowalewski M., Cortese B., Kandzari D., Dias S., Wojakowski W., Buffon A., Lansky A., Angelini P., Torguson R., et al.  Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis. 2014;233:224–231. doi: 10.1016/j.atherosclerosis.2013.12.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.atherosclerosis.2013.12.024</ArticleId>
            <ArticleId IdType="pubmed">24529148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya G., Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug. Deliv. Rev. 2006;58:387–401. doi: 10.1016/j.addr.2006.01.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2006.01.016</ArticleId>
            <ArticleId IdType="pubmed">16546289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiruppathi E., Mani G. Vitamin-c delivery from CoCr alloy surfacesusing polymer-free and polymer-based platforms for cardiovascular stent applications. Langmuir. 2014;30:6237–6249. doi: 10.1021/la501448h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/la501448h</ArticleId>
            <ArticleId IdType="pubmed">24832897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallo A., Mani G. A stent for co-delivering paclitaxel and nitric oxide from abluminal and luminal surfaces: Preparation, Surface characterization, and in vitro drug release studies. Appl Surf. Sci. 2013;279:216–232. doi: 10.1016/j.apsusc.2013.04.072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apsusc.2013.04.072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani G., Torres N., Oh S. Paclitaxel delivery from cobalt-chromium alloy surfaces using self-assembled monolayers. Biointerphases. 2011;6:33–42. doi: 10.1116/1.3575530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1116/1.3575530</ArticleId>
            <ArticleId IdType="pubmed">21721838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster S., Kakade S., Mani G. Microrough cobalt–chromium alloy surfaces for paclitaxel delivery: Preparation, characterization, and in vitro drug release studies. Langmuir. 2012;28:11511–11526. doi: 10.1021/la301636z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/la301636z</ArticleId>
            <ArticleId IdType="pubmed">22720656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujino I., Ako J., Honda Y., Fitzgerald P.J. Drug delivery via nano-, micro and macroporous coronary stent surfaces. Expert Opin. Drug Deliv. 2007;4:287–295. doi: 10.1517/17425247.4.3.287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425247.4.3.287</ArticleId>
            <ArticleId IdType="pubmed">17489655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wessely R., Hausleiter J., Michaelis C., Jaschke B., Vogeser M., Milz S., Behnisch B., Schratzenstaller T., Gluszko-Renke M., Stöver M., et al.  Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb. Vasc. Biol. 2005;25:748–753. doi: 10.1161/01.ATV.0000157579.52566.ee.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.ATV.0000157579.52566.ee</ArticleId>
            <ArticleId IdType="pubmed">15681298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morice M.C., Bestehorn H.P., Carrié D., Macaya C., Aengevaeren W., Wijns W., Dubois C., de Winter R., Verheye S., Hoffmann S., et al.  Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II Trial. EuroIntervention. 2006;2:45–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19755236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakade S., Mani G. A comparative study of the effects of vitamin C, sirolimus, and paclitaxel on the growth of endothelial and smooth muscle cells for cardiovascular medical device applications. Drug Des. Dev. Ther. 2013;7:529–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3699137</ArticleId>
            <ArticleId IdType="pubmed">23836963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popat A., Hartono S.B., Stahr F., Liu J., Qiao S.Z., Lu G.Q.M. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale. 2011;3:2801–2818. doi: 10.1039/c1nr10224a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c1nr10224a</ArticleId>
            <ArticleId IdType="pubmed">21547299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivero-Escoto J.L., Slowing I.I., Trewyn B.G., Lin V.S.Y. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010;6:1952–1967. doi: 10.1002/smll.200901789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/smll.200901789</ArticleId>
            <ArticleId IdType="pubmed">20690133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Shizhang Q., Yonggang J., Yang H., Budihartono S., Stahr F., Yan Z., Wang X., Hao Z., Lu G.Q. Fabrication and size-selective bioseparation of magnetic silica nanospheres with highly ordered periodic mesostructure. Adv. Func. Mater. 2008;18:3203–3212. doi: 10.1002/adfm.200800363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adfm.200800363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Zhang W., Zhang J., Sun W., Zhang R., Gu H. Fabrication of a novel polymer-free nanostructured drug-eluting coating for cardiovascular stents. ACS Appl. Mater. Interfaces. 2013;5:10337–10345. doi: 10.1021/am403365j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/am403365j</ArticleId>
            <ArticleId IdType="pubmed">24066711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alviar C.L., Tellez A., Wang M., Potts P., Smith D., Tsui M., Budzynski W., Raizner A.E., Kleiman N.S., Lev E.I., et al.  Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo. J. Thromb. Thrombolysis. 2012;34:91–98. doi: 10.1007/s11239-012-0696-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11239-012-0696-8</ArticleId>
            <ArticleId IdType="pubmed">22350685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa J.R., Abizaid A., Costa R., Feres F., Tanajura L.F., Abizaid A., Maldonado G., Staico R., Siqueira D., Sousa A.G.M.R., et al.  1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: The VESTASYNC I trial. JACC. 2009;2:422–427. doi: 10.1016/j.jcin.2009.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2009.02.009</ArticleId>
            <ArticleId IdType="pubmed">19463465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsiao H.M., Chiu Y.H., Wu T.Y., Shen J.K., Lee T.Y. Effects of through-hole drug reservoirs on key clinical attributes for drugeluting depot stent. Med. Eng. Phys. 2013;35:884–897. doi: 10.1016/j.medengphy.2012.08.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medengphy.2012.08.021</ArticleId>
            <ArticleId IdType="pubmed">22995147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S.J., Jo H.H., Lim K.S., Lim D., Lee S., Lee J.H., Kim W.D., Jeong M.H., Lim J.Y., Kwon I.K., et al.  Heparin coating on 3D printed poly (l-lactic acid) biodegradable cardiovascular stent via mild surface modification approach for coronary artery implantation. Chem. Eng. J. 2019;378:122116. doi: 10.1016/j.cej.2019.122116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cej.2019.122116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C.H., Hsieh M.J., Chang S.H., Hung K.C., Wang C.J., Hsu M.Y., Juang J.H., Hsieh I.C., Wen M.S., Liu S.J. Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: In vitro and in vivo. Int. J. Nanomed. 2019;14:7503–7513. doi: 10.2147/IJN.S211898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S211898</ArticleId>
            <ArticleId IdType="pmc">PMC6751553</ArticleId>
            <ArticleId IdType="pubmed">31686818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell R.G., Kennedy D.W. What is new and promising with drug-eluting stents in sinus surgery? Curr. Opin. Otolaryngol. Head Neck Surg. 2014;22:2–7. doi: 10.1097/MOO.0000000000000012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOO.0000000000000012</ArticleId>
            <ArticleId IdType="pubmed">24275800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh A., Anand U., Ugwu M.C., Feridooni T., Massoud E., Agu R.U. Drug-eluting Nasal Implants: Formulation, Characterization, Clinical Applications and Challenges. Pharmaceutics. 2014;6:249–267. doi: 10.3390/pharmaceutics6020249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics6020249</ArticleId>
            <ArticleId IdType="pmc">PMC4085598</ArticleId>
            <ArticleId IdType="pubmed">24871904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao R., Lu L., Zhang R., Hu J., Ni J., Shen W. Triptolide inhibits rat vascular smooth muscle cell proliferation and cell cycle progression via attenuation of ERK1/2 and Rb phosphorylation. Exp. Mol. Pathol. 2011;90:137–142. doi: 10.1016/j.yexmp.2010.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexmp.2010.12.001</ArticleId>
            <ArticleId IdType="pubmed">21167829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.W.Y., Lee B.S., Lee J.Y., Ku H.J., Jeon S.R., Kim J.Y., Ban J.M., Sung S.H., Shin H.M., Park J.E. The herbal extract HMC05 inhibits neointima formation in balloon-injured rat carotid arteries: Possible therapeutic implications of HMC05. J. Ethnopharmacol. 2011;133:168–176. doi: 10.1016/j.jep.2010.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jep.2010.09.015</ArticleId>
            <ArticleId IdType="pubmed">20883768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karki R., Jeon E.R., Kim D.W. Magnoliae cortex inhibits intimal thickening of carotid artery through modulation of proliferation and migration of vascular smooth muscle cells. Food Chem. Toxicol. 2012;50:634–640. doi: 10.1016/j.fct.2011.11.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2011.11.043</ArticleId>
            <ArticleId IdType="pubmed">22142686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trzeciak P. Drug eluting balloons-new weapon in the treatment of coronary artery disease? Choroby Serca Naczyń. 2011;8:12–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Serruys P.W., Kutryk M.J.B., Ong A.T.L. Coronary stents. N. Engl. J. Med. 2006;354:483–495. doi: 10.1056/NEJMra051091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra051091</ArticleId>
            <ArticleId IdType="pubmed">16452560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O’Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., et al.  TAXUS-IV Investigators, A polymer-based, paclitaxel-eluting stentin patients with coronary artery disease. N. Engl. J. Med. 2004;350:221–231. doi: 10.1056/NEJMoa032441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa032441</ArticleId>
            <ArticleId IdType="pubmed">14724301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sousa J.E., Costa M.A., Abizaid A., Feres F., Seixas A.C., Tanajura L.F., Mattos L.A., Falotico R., Jaeger J., Popma J.J., et al.  Four-year angiographic and intrava-scular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005;111:2326–2329. doi: 10.1161/01.CIR.0000164271.01172.1A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000164271.01172.1A</ArticleId>
            <ArticleId IdType="pubmed">15851603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauri L., Hsieh W.H., Massaro J.M., Ho K.K.L., D’Agostino R., Cutlip D.E. Stent thrombosis in randomized clini-cal trials of drug-eluting-stents. N. Engl. J. Med. 2007;356:1010–1029. doi: 10.1056/NEJMoa067731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa067731</ArticleId>
            <ArticleId IdType="pubmed">17296821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchis-Gomar F., Perez-Quilis C., Leischik R., Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann. Transl. Med. 2016;4:1–12. doi: 10.21037/atm.2016.06.33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm.2016.06.33</ArticleId>
            <ArticleId IdType="pmc">PMC4958723</ArticleId>
            <ArticleId IdType="pubmed">27500157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naghi J., Yalvac E., Pourdjabbar A., Ang L., Bahadorani J., Reeves R., Mahmud E., Patel M. New developments in the clinical use of drug-coated balloon catheters in peripheral arterial disease Review. Med. Devices Evid. Res. 2016;9:161–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4935119</ArticleId>
            <ArticleId IdType="pubmed">27418859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrne R.A., Joner M., Alfonso F., Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease Review. Nat. Rev. 2014;11:13–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24189405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schorn I., Malinoff H., Anderson S., Lecy C., Wang J., Giorgianni J., Papandreou G. The LUTONIX® drug-coated balloon: A novel drug delivery technology forthe treatment of vascular disease. Adv. Drug Deliv. Rev. 2017;112:78–87. doi: 10.1016/j.addr.2017.05.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2017.05.015</ArticleId>
            <ArticleId IdType="pubmed">28559093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortesea B., Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: A comprehensive review of preclinical and clinical data. Int. J. Cardiol. 2012;161:4–12. doi: 10.1016/j.ijcard.2011.08.855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2011.08.855</ArticleId>
            <ArticleId IdType="pubmed">21955612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loh J.P., Waksman R. Paclitaxel Drug-Coated Balloons, A Review of Current Status and Emerging Applicationsin Native Coronary Artery De Novo Lesions. J. Am. Coll. Cardiol. Intv. 2012;5:1002–1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23078727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsanos K., Kitrou P., Spiliopoulos S., Diamantopoulos A., Karnabatidis D. Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease: Systematic Review and Bayesian Network Meta-analysis of Randomized Controlled Trials. J. Endovasc. Ther. 2016;6:851–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27708143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Xu X., Kong J., Xu R., Fan X., Chen J., Zheng X., Ma B., Sun M., Ye Z., et al.  Systematic Review and Meta-Analysis of Drug-Eluting Balloon and Stent for Infrapopliteal Artery Revascularization. Vasc. Endovasc. Surg. 2017;51:72–83. doi: 10.1177/1538574416689426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1538574416689426</ArticleId>
            <ArticleId IdType="pubmed">28103754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsanos K., Spiliopoulos S., Karunanithy N., Krokidis M., Sabharwal T., Taylor P. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J. Vasc. Surg. 2014;59:1123–1133.e8. doi: 10.1016/j.jvs.2014.01.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvs.2014.01.041</ArticleId>
            <ArticleId IdType="pubmed">24661896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiliopoulos S., Kamarinos N.V., Brountzos E. Current evidence of drug-elution therapy for infrapopliteal arterial disease. Current evidence of drug-elution therapy for infrapopliteal arterial disease. World J. Cardiol. 2019;11:13–23. doi: 10.4330/wjc.v11.i1.13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4330/wjc.v11.i1.13</ArticleId>
            <ArticleId IdType="pmc">PMC6354073</ArticleId>
            <ArticleId IdType="pubmed">30705739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Li J., Zheng C., He Y., Jia J., Wang X., Li D., Shang T., Li M. Drug-delivering endovascular treatment versus angioplasty in artery occlusion diseases: A systematic review and meta-analysis. Curr. Med. Res. Opin. 2018;34:95–105. doi: 10.1080/03007995.2017.1372114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03007995.2017.1372114</ArticleId>
            <ArticleId IdType="pubmed">28837370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caradu C., Lakhlifi E., Colacchio E.C., Midy D., Bérard X., Poirier M., Ducasse E. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J. Vasc. Surg. 2019;70:981–995. doi: 10.1016/j.jvs.2019.01.080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvs.2019.01.080</ArticleId>
            <ArticleId IdType="pubmed">31126769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J.Q., Peng J.H., Xu T., Liu L.Y., Tu J.H., Li S.H., Chen H. Meta-analysis of the effects of drug-coated balloons among patients with small-vessel coronary artery disease. Medicine. 2019;98:e15797. doi: 10.1097/MD.0000000000015797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000015797</ArticleId>
            <ArticleId IdType="pmc">PMC6709063</ArticleId>
            <ArticleId IdType="pubmed">31145306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Guo C., Lv Y.H., Zhang M.B., Wang Z.L. Drug-coated balloon versus drug-eluting stent in de novo small coronary vessel disease: A systematic review and meta-analysis. Medicine. 2019;98:e15622. doi: 10.1097/MD.0000000000015622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000015622</ArticleId>
            <ArticleId IdType="pmc">PMC6571399</ArticleId>
            <ArticleId IdType="pubmed">31124941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayssi A., Al-Jundi W., Papia G., Kucey D.S., Forbes T., Rajan D.K., Neville R., Dueck A.D. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. Cochrane Database Syst. Rev. 2019;1:CD012510. doi: 10.1002/14651858.CD012510.pub2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD012510.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6353053</ArticleId>
            <ArticleId IdType="pubmed">30684445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindquist J., Schramm K. Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease. Semin. Int. Radiol. 2018;35:443–452. doi: 10.1055/s-0038-1676360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0038-1676360</ArticleId>
            <ArticleId IdType="pmc">PMC6363541</ArticleId>
            <ArticleId IdType="pubmed">30728660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohiaddin H., Wong T.D.F.K., Burke-Gaffney A., Bogle R.G. Drug-Coated Balloon-Only Percutaneous Coronary Intervention for the Treatment of De Novo Coronary Artery Disease: A Systematic Review. Cardiol. Ther. 2018;7:127–149. doi: 10.1007/s40119-018-0121-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40119-018-0121-2</ArticleId>
            <ArticleId IdType="pmc">PMC6251821</ArticleId>
            <ArticleId IdType="pubmed">30368735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S.B., Worme M., Yanagawa B., Kumar N., Buller C.E., Cheema A.N., Bagai A. Treatment of Drug-Eluting Stent In-Stent Restenosis with Drug-Eluting Balloons: A Systematic Review and Meta-Analysis. J. Invasive Cardiol. 2018;30:360–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30108189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meneguz-Moreno R.A., Costa J.R., Abizaid A. Drug-Coated Balloons: Hope or Hot Air: Update on the Role of Coronary DCB. Curr. Cardiol. Rep. 2018;20:100. doi: 10.1007/s11886-018-1025-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11886-018-1025-4</ArticleId>
            <ArticleId IdType="pubmed">30171374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokkinidis D.G., Prouse A.F., Avner S.J., Lee J.M., Waldo S.W., Armstrong E.J. Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 2018;92:285–299. doi: 10.1002/ccd.27359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ccd.27359</ArticleId>
            <ArticleId IdType="pubmed">29024274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merinopoulos I., Gunawardena T., Wickramarachchi U., Ryding A., Eccleshall S., Vassiliou V.S. Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future? Curr. Cardiol. Rev. 2018;14:45–52. doi: 10.2174/1573403X14666171226144120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1573403X14666171226144120</ArticleId>
            <ArticleId IdType="pmc">PMC5872262</ArticleId>
            <ArticleId IdType="pubmed">29278215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg M.C., Kolodziej H., Cremers B., Gershony G., Speck U. Drug-coated angioplasty balloon catheters: Coating compositions and methods. Adv. Eng. Mater. 2012;14:B45–B50. doi: 10.1002/adem.201180067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adem.201180067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy S.B. Balloon and Manufacture Thereof. Application No. 07/287,234. US Patent. 1984 Dec 25</Citation>
        </Reference>
        <Reference>
          <Citation>Lixiao W., Jianhua C.N.L. Laminate Catheter Balloons with Additive Burst Strength and Methods for Preparation of Same. Specification US 6124007 A. US Patent. 2000 Sep 26;</Citation>
        </Reference>
        <Reference>
          <Citation>Roorda W.E. Biocompatible Carrier Containing a Bioadhesive Material. Specification US 8,728,510. US Patent. 2014 May 20;</Citation>
        </Reference>
        <Reference>
          <Citation>Zou W., Cao G., Xi Y., Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv. 2009;16:15–23. doi: 10.1080/10717540802481307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10717540802481307</ArticleId>
            <ArticleId IdType="pubmed">19555304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacetti S., Stankus J.D. Coating on a Balloon Comprising a Polymer and a Drug. Specification US 8367090 B2. US Patent. 2013 Feb 5;</Citation>
        </Reference>
        <Reference>
          <Citation>Radhakrishnan R., Larsen S., Schewe S., Feng J., Warner R., Folan M., Flanagan A., Clarke J., O’connor T., Malone A. Drug Eluting Medical Device Utilizing Bioadhesives. Specification US 20120095396 A1. US Patent. 2012 Apr 19;</Citation>
        </Reference>
        <Reference>
          <Citation>Gertz Z.M., Wilensky R.L. Local Drug Delivery for Treatment of Coronary and Peripheral Artery Disease. Cardiovasc. Ther. 2011;29:e54–e66. doi: 10.1111/j.1755-5922.2010.00187.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1755-5922.2010.00187.x</ArticleId>
            <ArticleId IdType="pubmed">20553281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang H.G., Azar D.A., Lyle C., Chitalia V.C., Shazly T., Kolachalama V.B. Intrinsic coating morphology. Sci. Rep. 2019;9:6839. doi: 10.1038/s41598-019-43095-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-43095-9</ArticleId>
            <ArticleId IdType="pmc">PMC6497887</ArticleId>
            <ArticleId IdType="pubmed">31048704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tepe G., Schnorr B., Albrecht T., Brechtel K., Claussen C.D., Scheller B., Speck U., Zeller T. Angioplasty of Femoral-Popliteal Arteries with Drug-Coated Balloons: 5-Year Follow-Up of the THUNDER Trial. JACC Cardiovasc. Interv. 2015;8:102–108. doi: 10.1016/j.jcin.2014.07.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2014.07.023</ArticleId>
            <ArticleId IdType="pubmed">25616822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner E.A., Atigh M.K., Erwin M.M., Christians U., Yazdani S.K. Coating and pharmacokinetic evaluation of air spray coated drug coated balloons. Cardiovasc. Eng. Technol. 2018;9:240–250. doi: 10.1007/s13239-018-0346-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13239-018-0346-1</ArticleId>
            <ArticleId IdType="pmc">PMC5990435</ArticleId>
            <ArticleId IdType="pubmed">29497966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese B., Micheli A., Picchi A., Coppolaro A., Bandinelli L., Severi S., Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomized clinical trial. Heart. 2010;96:1291–1296. doi: 10.1136/hrt.2010.195057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/hrt.2010.195057</ArticleId>
            <ArticleId IdType="pubmed">20659948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheinert D., Duda S., Zeller T., Krankenberg H., Ricke J., Bosiers M., Tepe G., Naisbitt S., Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: First-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc. Interv. 2014;7:10–19. doi: 10.1016/j.jcin.2013.05.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2013.05.022</ArticleId>
            <ArticleId IdType="pubmed">24456716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pósa A., Nyolczas N., Hemetsberger R., Pavo N., Petnehazy O., Petrasi Z., Sangiorgi G., Gyongyosi M. Optimization of drug-eluting balloon use for safety and efficacy: Evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries, Catheter. Cardiovasc. Interv. 2010;76:395–403. doi: 10.1002/ccd.22468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ccd.22468</ArticleId>
            <ArticleId IdType="pubmed">20839356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheller B., Speck U., Romeike B., Schmitt A., Sovak M., Böhm M., Stoll H.P. Contrast media as carriers for local drug delivery Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur. Heart J. 2003;24:1462–1467. doi: 10.1016/S0195-668X(03)00317-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0195-668X(03)00317-8</ArticleId>
            <ArticleId IdType="pubmed">12909076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hehrlein C., Richardt G., Wiemer M., Schneider H., Naber C., Hoffmann E., Dietz U. Description of Pantera Lux paclitaxel-releasing balloon and preliminary quantitative coronary angiography (QCA) results at six months in patients with coronary in-stent restenosis. EuroIntervention. 2011;7(Suppl. K):K119–K124. doi: 10.4244/EIJV7SKA20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4244/EIJV7SKA20</ArticleId>
            <ArticleId IdType="pubmed">22027721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder H., Meyer D.R., Lux B., Ruecker F., Martorana M., Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first-inhuman study. Catheter Cardiovasc. Interv. 2015;86:278–286. doi: 10.1002/ccd.25900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ccd.25900</ArticleId>
            <ArticleId IdType="pmc">PMC6585947</ArticleId>
            <ArticleId IdType="pubmed">25708850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raval A., Parikh J., Engineer C. Mechanism of Controlled Release Kinetics from Medical Devices. Braz. J. Chem. Eng. 2010;27:211–225. doi: 10.1590/S0104-66322010000200001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S0104-66322010000200001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sternberg K., Kramer S., Nischan C., Grabow N., Langer T., Hennighausen G., Schmitz K.P. In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A—Drug release, polymer degradation and mechanical integrity. J. Mater. Sci. Mater. Med. 2007;18:1423–1432. doi: 10.1007/s10856-007-0148-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10856-007-0148-8</ArticleId>
            <ArticleId IdType="pubmed">17387586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L. Drug Releasing Coatings for Medical Devices. US9289539B22016. US Patent. 2016 Mar 22;</Citation>
        </Reference>
        <Reference>
          <Citation>Ruebben A., Boeing J., Weiss N. Usage of different vessel models in a flow-through cell: In vitro study of a novel coated balloon catheter. Int. Cardiol. Rev. 2011;6:56–57.</Citation>
        </Reference>
        <Reference>
          <Citation>Byrne R.A., Neumann F.J., Mehilli J., Pinieck S., Wolff B., Tiroch K., Schulz S., Fusaro M., Ott I., Ibrahim T., et al.  Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, open-label trial. Lancet. 2013;381:461–467. doi: 10.1016/S0140-6736(12)61964-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)61964-3</ArticleId>
            <ArticleId IdType="pubmed">23206837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg M.C., Speck T. Drug-Coated Medical Devices. Specification US 9,233,191. US Patent. 2016 Jan 12;</Citation>
        </Reference>
        <Reference>
          <Citation>Stankus J., Trollsas M., Hossainy S. Coatings with Tunable Solubility Profile for Drug-Coated Balloon. Application 8480620 B2. US Patent. 2013 Jul 9;</Citation>
        </Reference>
        <Reference>
          <Citation>Paclitaxel-Eluting Balloon Essential Catheter by i Vascula.  [(accessed on 28 September 2020)]; Available online:  http://ivascular.global/coronary/essential/</Citation>
        </Reference>
        <Reference>
          <Citation>Speck U. Formulations for Drug-Coated Medical Devices. Application 14/350,483. US Patent. 2016 Aug 16;</Citation>
        </Reference>
        <Reference>
          <Citation>Borck A. Balloon Catheter Having Coating. Specification 8,486,013. US Patent. 2013 Jul 16;</Citation>
        </Reference>
        <Reference>
          <Citation>Gandhi P.J., Murthy Z.V.P. Investigation of Different Drug Deposition Techniques on Drug Releasing Properties of Cardiovascular Drug Coated Balloons. Ind. Eng. Chem. Res. 2012;51:10800–10823. doi: 10.1021/ie3006676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ie3006676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen S., Kaule S., Stein F., Minrath I., Schmitz K.P., Kragl U., Sternberg K. Novel Paclitaxel-Coated Angioplasty Balloon Catheter Based on Cetylpyridinium Salicylate: Preparation, Characterization and Simulated Use in an in Vitro Vessel Model Mater. Sci. Eng. C Mater. Biol. Appl. 2013;33:4244–4250. doi: 10.1016/j.msec.2013.06.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msec.2013.06.021</ArticleId>
            <ArticleId IdType="pubmed">23910339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amundson R.R., Hull V.W., Dror M., Schwartz R.S. Method for Making a Drug Delivery Balloon Catheter. Specification 5,370,614. US Patent. 1994 Dec 6;</Citation>
        </Reference>
        <Reference>
          <Citation>Hull V.W., Schwartz R.S., Dror M. Releasable Microcapsules on Balloon Catheters. Specification 5,893,840. US Patent. 1999 Apr 13;</Citation>
        </Reference>
        <Reference>
          <Citation>Palasis M. Multi-Balloon Catheter with Hydrogel Coating. Specification 7,060,051. US Patent. 2006 Jun 13;</Citation>
        </Reference>
        <Reference>
          <Citation>Christiansen F.K. Drug Eluting Balloon. No. 8211055 B2. US Patent. 2012 Jul 3</Citation>
        </Reference>
        <Reference>
          <Citation>Speck U. Lmus-Coated Medical Devices. Application 13/641,490. US Patent. 2017 Apr 25;</Citation>
        </Reference>
        <Reference>
          <Citation>Orlowski M. Shellac and Paclitaxel Coated Catheter Balloons. Application 13/266,059. US Patent. 2019 May 21;</Citation>
        </Reference>
        <Reference>
          <Citation>Von Strandmann R.P. Catheter Balloon Coated with Rapamycin and Shella. Application 14/113,953. US Patent. 2014 Apr 17;</Citation>
        </Reference>
        <Reference>
          <Citation>Rowe S.J. Ethod and Apparatus for Delivery Stokes of Therapeuticagent. Specification 6,616,650. US Patent. 2003 Sep 9;</Citation>
        </Reference>
        <Reference>
          <Citation>Clarke J.T., Weber J., Flanagan A. Drug-Delivery Balloons. Application 12/961,927. US Patent. 2011 Jun 30;</Citation>
        </Reference>
        <Reference>
          <Citation>Weber J., Clarke J.T., Flanagan A. Alloon Catheters with Fibers for Delivery of Therapeuticagent and Methods of Making the Same. Specification 9,227,041. US Patent. 2016 Jan 5;</Citation>
        </Reference>
        <Reference>
          <Citation>Nordmann A.J., Briel M., Bucher H.C. Mortality in randomizedcontrolled trials comparing drug-eluting vs. bare metal stents incoronary artery disease: A meta-analysis. Eur. Heart J. 2006;27:2784–2814. doi: 10.1093/eurheartj/ehl282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehl282</ArticleId>
            <ArticleId IdType="pubmed">17020889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camenzind E., Steg P.G., Wijns W. Stent thrombosis late afterimplantation of first-generation drug-eluting stents: A cause forconcern. Circulation. 2007;115:1440–1455. doi: 10.1161/CIRCULATIONAHA.106.666800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.666800</ArticleId>
            <ArticleId IdType="pubmed">17344324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagerqvist B., James S.K., Stenestrand U., Lindbäck J., Nilsson T., Wallentin L., SCAAR Study Group  Long-term outcomeswith drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007;356:1009–1019. doi: 10.1056/NEJMoa067722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa067722</ArticleId>
            <ArticleId IdType="pubmed">17296822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg S., Serruys P.W. Coronary stents: Looking forward. J. Am. Coll Cardiol. 2010;56:S43–S78. doi: 10.1016/j.jacc.2010.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2010.06.008</ArticleId>
            <ArticleId IdType="pubmed">20797503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silber S., Borggrefe M., Böhm M., Hoffmeister H.M., Dietz R., Ertl G., Heusch G. Drug-eluting coronary stentsand drug eluting balloon catheters: Summary of the positionpapers of the DGK. Clin. Res. Cardiol. 2008;97:548–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18726643</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
